ReviewAdvances in chronic kidney disease2018
The Global Epidemiology of Diabetes and Kidney Disease.
Review in Advances in chronic kidney disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 360 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
360 citing papers in PubMed, 8 syntheses or guidelines pooled it, 654 citations in OpenAlex.
- Diabetic Foot Ulceration in Dialysis-Dependent End-Stage Kidney Disease: A Systematic Review of Epidemiology, Clinical Outcomes and Mortality Risk.Diabetes/metabolism research and reviews · 2026Pooled it
- The diagnostic value of immune-inflammatory markers for diabetic kidney disease in type 2 diabetic patients: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Association of growth differentiation factor-15 with renal disease outcomes and all-cause death in type 1 and type 2 diabetic patients: a meta-analysis.BMC nephrology · 2025Pooled it
- Acute myocardial infarction treatment delay in South Asia: a systematic review and meta-analysis.Future cardiology · 2025Pooled it
- Association of finerenone with prognosis and safety in diabetic kidney disease patients: an undated meta-analysis based on four RCTs.Frontiers in medicine · 2025Pooled it
- Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods.Frontiers in pharmacology · 2025Pooled it
- Machine learning-based risk predictive models for diabetic kidney disease in type 2 diabetes mellitus patients: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Determinants of diabetic nephropathy among diabetic patients in Ethiopia: Systematic review and meta-analysis.PloS one · 2024Pooled it
- Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.Diabetes, obesity & metabolism · 2026Trial
- The impact of automated insulin delivery on glucose management in people with diabetes and advanced chronic kidney disease.Diabetologia · 2026Trial
- Rate and risk factors of kidney function decline among South Asians with type 2 diabetes: analysis of the CARRS Trial.BMJ open diabetes research & care · 2024Trial
- Effect of exercise-based rehabilitation on functional capacity and renal function in type 2 diabetes mellitus with nephropathy: a randomized controlled trial.International urology and nephrology · 2024Trial
- The effects of multifactorial pharmacist-led intervention protocol on medication optimisation and adherence among patients with type 2 diabetes: A randomised control trial.F1000Research · 2024Trial
- Heterogeneous 30-day readmission risk in diabetic kidney disease: a nationwide analysis stratified by phenotype, age, and socioeconomic status.International urology and nephrology · 2026Article
- Clinical utility of transient elastography for assessing prevalent coronary heart disease in individuals with type 2 diabetes mellitus.Acta diabetologica · 2026Article
- Article
- Cardiovascular-Kidney-Metabolic Syndrome: Conceptualising an Approach to Health Economic Modelling.Diabetes, obesity & metabolism · 2026Review
- Individual and Contextual Socioeconomic Position on Type 2 Diabetes Risk in LMICs: A Multilevel Analysis.Annals of the New York Academy of Sciences · 2026Article
- Article
- Observational
300 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
The prevalence of diabetes is increasing worldwide, with the greatest increases occurring in low- and middle-income countries. In most developed countries, type 2 diabetes is presently the leading cause of end-stage renal disease and also contributes substantially to cardiovascular disease. In countries with weaker economies type 2 diabetes is rapidly replacing communicable diseases as a leading cause of kidney disease and is increasingly competing for scarce health care resources. Here, we present a narrative review of the prevalence and incidence of diabetes-related kidney disease worldwide. Mortality among those with diabetes and kidney disease will also be explored. Given the high morbidity and mortality associated with chronic kidney disease, we will also examine the level of awareness of this disease among people who have it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.